Skin Disorders News

Adults treated with amlitelimab showed sustained improvement in their moderate to severe atopic dermatitis over the span of 28 weeks, Sanofi announced in a press release.

The FDA has cleared InnoCare Pharma’s investigational new drug application for ICP-332, according to a press release.

Patients with chronic spontaneous urticaria experienced early symptom improvements that were sustained through 52 weeks with remibrutinib, according to a presentation at the European Academy of Allergy & Clinical Immunology Congress.

In order to better manage symptoms of atopic dermatitis, health care professionals must consider aggravating factors and systemic immunotherapy, according to a study published in the Chinese Medical Journal.

Abrocitinib may be an effective and well-tolerated treatment for adults with prurigo nodularis and chronic pruritus of unknown origins, according to a study.

Roflumilast cream 0.15% demonstrated long-term efficacy and tolerability in adults and children aged 6 years and older with atopic dermatitis, Arcutis announced in a press release.

Both organic and inorganic pigments used in cosmetic tattoos, also known as permanent makeup, may cause allergic contact dermatitis, according to a study.

CLEVELAND — For patients with atopic dermatitis, today’s systemic therapies can lead to long-standing on-drug relief, but long-term, off-drug remission remains a goal that has yet to be reached, according to Raj Chovatiya, MD, PhD.

CLEVELAND — For patients with chronic spontaneous urticaria, lab testing can help to phenotype disease and guide treatment, according to James Fernandez, MD, PhD, an allergy and immunology specialist at the Cleveland Clinic.

Dermatologist Raj Chovatiya, MD, PhD, MSCI, recently spoke to Healio about his new findings in seborrheic dermatitis and how to best treat diverse patient groups with this condition.